Antios Therapeutics: Funding, Investors & Team (Sep 2026)
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.
Antios Therapeutics has raised $96.0M across 1 funding round on record, the most recent a Series B of $96.0M announced in Apr 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Antios Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2021.
Antios Therapeutics Funding Rounds
Antios Therapeutics Founders and Leadership Team
Contact details for the Antios Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Antios Therapeutics Funding Compared to Other Biotechnology Startups
Antios Therapeutics' latest round of $96.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Antios Therapeutics in Biotechnology and Atlanta
Companies Similar to Antios Therapeutics
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Antios Therapeutics Funding FAQs
What does Antios Therapeutics do?
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.
How much funding has Antios Therapeutics raised?
Antios Therapeutics has raised $96.0M across 1 round on record. The most recent is a Series B of $96.0M announced in Apr 2021.
When did Antios Therapeutics last raise funding?
Antios Therapeutics' most recent funding round on record is a Series B of $96.0M, announced in Apr 2021.
Who is the CEO of Antios Therapeutics?
Greg Mayes is listed as CEO at Antios Therapeutics.
Where is Antios Therapeutics headquartered?
Antios Therapeutics is based in Atlanta, Georgia, United States.
How many employees does Antios Therapeutics have?
Antios Therapeutics is in the 11-50 employee band.
How does Antios Therapeutics' funding compare to other Biotechnology startups?
Antios Therapeutics' latest round of $96.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Antios Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Antios Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.